3. It is also recommended that quotas of production be sharply curtailed to at least less than 10 percent of present production for those pharmaceuticals that are recommended for use in some condition other than obesity. Drugs marketed only for use in obesity that have abuse potential may well be forced to withdraw from the market.

4. Eliminate the manufacture of combinations of pharmaceuticals involving this class of drug and of all intravenous preparations.

5. Enforce the efficacy and safety regulations for drugs and require that all agents proposed for the treatment of obesity in the future pass the test of efficacy and safety before acceptance by the FDA based on an FDA regulated protocol designed to eliminate trivial products.

6. Eliminate the over-the-counter pharmaceuticals since they have been found to be entirely worthless in the treatment of obesity. It is much too costly for the government to tackle these one by one under trade name when the company need only change its name and the name of the product and be out from under the law again. All such preparations should be eliminated as worthless unless they can pass the standards set by FDA for new products.

Although this would, in effect, impliment the concerns of the Committee in relation to its single-minded pursuit of the relation of these compounds to the treatment of obesity, it would not take care of other very real problems. The bigger question that needs to be reviewed is the rapacious attitude of